ADP核糖基化因子样GTP酶4C（ARL4C）通过上调醛脱氢酶1A3（ALDH1A3）增强胶质母细胞瘤细胞的干细胞样特性。

ADP-Ribosylation Factor Like GTPase 4C (ARL4C) augments stem-like traits of glioblastoma cells by upregulating ALDH1A3.

作者信息

Chen Qian, Fu Wen-Juan, Tang Xiao-Peng, Wang Lu, Niu Qin, Wang Shuai, Lin Yong, Cao Mian-Fu, Hu Rong, Wen Hai-Yan, Wang Yan, Zhang Xia, Yao Xiao-Hong

机构信息

Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China.

Cancer Center of Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China.

出版信息

J Cancer. 2021 Jan 1;12(3):818-826. doi: 10.7150/jca.45052. eCollection 2021.

Glioma cells with stem cell-like properties are crucial for tumor initiation, progression and therapeutic resistance. Therefore, identifying specific factors in regulating stem-like traits is critical for the design of novel glioma therapeutics. Herein, we reported that ADP-Ribosylation Factor Like GTPase 4C (ARL4C) was highly expressed in glioma stem-like cells (GSLCs). GSLCs, determined by the efficiency of sphere formation and tumor growth , was increased by overexpression of ARL4C. ARL4C induced the tumorigenesis through ALDH1A3. Analyses of 325 patient specimens showed that ARL4C was highly expressed in glioblastoma (GBM) as compared with lower grade gliomas. In addition, higher level ARL4C expression in glioma was correlated with poorer progression-free survival and overall survival of patients. Therefore, ARL4C may act as a novel prognostic marker and a therapeutic target for GBM.

具有干细胞样特性的胶质瘤细胞对肿瘤的起始、进展和治疗耐药性至关重要。因此，识别调节干细胞样特征的特定因子对于设计新型胶质瘤治疗方法至关重要。在此，我们报道了ADP核糖基化因子样GTP酶4C（ARL4C）在胶质瘤干细胞样细胞（GSLCs）中高表达。通过球体形成效率和肿瘤生长确定的GSLCs因ARL4C的过表达而增加。ARL4C通过ALDH1A3诱导肿瘤发生。对325例患者标本的分析表明，与低级别胶质瘤相比，胶质母细胞瘤（GBM）中ARL4C高表达。此外，胶质瘤中较高水平的ARL4C表达与患者较差的无进展生存期和总生存期相关。因此，ARL4C可能作为GBM的一种新型预后标志物和治疗靶点。